Biotech Values

[Dub Narcotic]

I think the Lilly/Elan secretase inhibitors are destined to be interesting failures. They are first generation compounds with too big a side effect profile and they are targeting mild/moderate disease at which point the amyloid cascade is too far advanced for upstream intervention to make a difference.